Seeking Alpha
24 Jul 2026, 13:45 UTC · 1h ago
Legend Biotech: Why I'm Ready To Go Long Again
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
24 Jul 2026, 13:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Carvykti sales reached $657 million in Q2, representing a 49.7% year-on-year increase. — Strong revenue growth and high demand for a key CAR-T therapy directly boost the valuation of both J&J and Legend Biotech.
+0.80Carvykti sales grew 10.1% quarter-on-quarter in the second quarter. — Consistent sequential growth suggests sustained market penetration and product adoption.
+0.40Which stocks this story touches
Reported continued strong demand and significant sales growth for Carvykti.
Continue reading
6 related stories
Top 1 mover · tap to explore
High sales of Carvykti suggest the company will likely beat consensus estimates for Q2.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
